16 / 19
Page 38
Notes:
conferenceseries
.com
Volume 20
International Journal of Emergency Mental Health & Human Resilience
World Mental Health 2018
July 16-18, 2018
July 16-18, 2018 Dubai, UAE
Public Mental Health and Neuroscience
29
th
International Conference on
Atherosclerosis and changed iron metabolism in chronic kidney disease
Victor Manolov
Medical University Sofia, Bulgaria
C
hronic kidney disease (CKD) involves high number of population worldwide, which on its way increases brain-vascular
diseases risk. Among the main reasons for increased brain disorders evidence in patients with CKD is iron homeostasis
disregulation. Impairment of brain cognitive function is an early sign of atherosclerosis development. 65 patients with chronic
kidney disease (stages II to V, incl on dialysis) were included; age 48.8 ± 6.9. Their results were compared to sex and age
matched healthy control and with CKD patients with no atherosclerotic changes. Routine blood analyses as CBC, serum
iron, ferritin, hsCRP and specific hepcidin were measured in the included groups. IMT, MMSE, CERAD tests were used for
atherosclerotic changes evaluation. We found increased serum hepcidin levels in CKD patients with IMT, MMSE, CERAD
changes (201.8 ± 14.7 μg/L) compared to healthy controls (20.7 ± 1.9 μg/L) and CKD with no atherosclerotic changes group
(174.4 ± 11.8 μg/L); P<0.005. A positive correlation was found in CKD patients with brain disorders between IMT and serum
hepcidin levels (r=0.838, P<0.01). Serum hepcidin correlates positively to atherosclerotic evidence changes in patients with
impaired kidney function (r=0.810, P<0.01). Brain-vascular disease risk factors are connected to chronic kidney function
impairment. Disregulation of iron homeostasis is one of the main risk atherogenesis factors. Early hepcidin quantification
might predict cognitive disturbances as atherosclerosis symptoms in chronic kidney disease patients, which might be very
important for better clinical diagnosis and practice.
Acknowledgements:
This project is sponsored by MU-Sofia, as part of Grant Д-235/2017.
Biography:
Victor Manolov has completed his PhD at Medical University in Sofia, Bulgaria. He is working as Assist. Prof. at Department
of Clinical laboratory and clinical immunology at the same University. His interests are in neurology, pediatrics, gynecology,
endocrinology and clinical laboratory. He has published more than 20 papers in reputed journals.
victhedoc4@abv.bgVictor Manolov, Int J Emerg Ment Health 2018, Volume 20
DOI: 10.4172/1522-4821-C2-014